338 related articles for article (PubMed ID: 19804814)
21. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.
Nuotio-Antar AM; Hachey DL; Hasty AH
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1517-28. PubMed ID: 17878220
[TBL] [Abstract][Full Text] [Related]
22. Upregulation of adipose 11-beta-hydroxysteroid dehydrogenase type 1 expression in ovariectomized rats is due to obesity rather than lack of estrogen.
Paulsen SK; Nielsen MP; Richelsen B; Bruun JM; Flyvbjerg A; Pedersen SB
Obesity (Silver Spring); 2008 Apr; 16(4):731-5. PubMed ID: 18379559
[TBL] [Abstract][Full Text] [Related]
23. 11Beta-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization.
Paulsen SK; Pedersen SB; Fisker S; Richelsen B
Obesity (Silver Spring); 2007 Aug; 15(8):1954-60. PubMed ID: 17712112
[TBL] [Abstract][Full Text] [Related]
24. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
Masuzaki H; Flier JS
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):255-62. PubMed ID: 14683456
[TBL] [Abstract][Full Text] [Related]
25. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
Walker BR
Proc Nutr Soc; 2007 Feb; 66(1):1-8. PubMed ID: 17343766
[TBL] [Abstract][Full Text] [Related]
26. 11beta-hydroxysteroid dehydrogenases: changing glucocorticoid action.
Seckl JR
Curr Opin Pharmacol; 2004 Dec; 4(6):597-602. PubMed ID: 15525550
[TBL] [Abstract][Full Text] [Related]
27. Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
Lloyd DJ; Helmering J; Cordover D; Bowsman M; Chen M; Hale C; Fordstrom P; Zhou M; Wang M; Kaufman SA; Véniant MM
Diabetes Obes Metab; 2009 Jul; 11(7):688-99. PubMed ID: 19527482
[TBL] [Abstract][Full Text] [Related]
28. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome.
Wang M
Curr Opin Investig Drugs; 2006 Apr; 7(4):319-23. PubMed ID: 16625818
[TBL] [Abstract][Full Text] [Related]
29. The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Stimson RH; Walker BR
Horm Mol Biol Clin Investig; 2013 Sep; 15(2):37-48. PubMed ID: 25436731
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of disease: Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome.
Tomlinson JW; Stewart PM
Nat Clin Pract Endocrinol Metab; 2005 Dec; 1(2):92-9. PubMed ID: 16929377
[TBL] [Abstract][Full Text] [Related]
31. 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients.
Desbriere R; Vuaroqueaux V; Achard V; Boullu-Ciocca S; Labuhn M; Dutour A; Grino M
Obesity (Silver Spring); 2006 May; 14(5):794-8. PubMed ID: 16855188
[TBL] [Abstract][Full Text] [Related]
32. Expression and activity of 11beta-hydroxysteroid dehydrogenase type 1 enzyme in subcutaneous and visceral adipose tissue of prepubertal children.
Mericq V; Medina P; Bouwman C; Johnson MC; Godoy J; López T; Iñiguez G
Horm Res; 2009; 71(2):89-93. PubMed ID: 19129713
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of 11beta-HSD1 as a novel treatment for the metabolic syndrome: do glucocorticoids play a role?
Thieringer R; Hermanowski-Vosatka A
Expert Rev Cardiovasc Ther; 2005 Sep; 3(5):911-24. PubMed ID: 16181035
[TBL] [Abstract][Full Text] [Related]
34. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents.
Boyle CD; Kowalski TJ
Expert Opin Ther Pat; 2009 Jun; 19(6):801-25. PubMed ID: 19456274
[TBL] [Abstract][Full Text] [Related]
35. Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue.
Apostolova G; Schweizer RA; Balazs Z; Kostadinova RM; Odermatt A
Am J Physiol Endocrinol Metab; 2005 May; 288(5):E957-64. PubMed ID: 15613680
[TBL] [Abstract][Full Text] [Related]
36. A transgenic model of visceral obesity and the metabolic syndrome.
Masuzaki H; Paterson J; Shinyama H; Morton NM; Mullins JJ; Seckl JR; Flier JS
Science; 2001 Dec; 294(5549):2166-70. PubMed ID: 11739957
[TBL] [Abstract][Full Text] [Related]
37. Human and rodent type 1 11beta-hydroxysteroid dehydrogenases are 7beta-hydroxycholesterol dehydrogenases involved in oxysterol metabolism.
Hult M; Elleby B; Shafqat N; Svensson S; Rane A; Jörnvall H; Abrahmsen L; Oppermann U
Cell Mol Life Sci; 2004 Apr; 61(7-8):992-9. PubMed ID: 15095019
[TBL] [Abstract][Full Text] [Related]
38. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity.
Rask E; Walker BR; Söderberg S; Livingstone DE; Eliasson M; Johnson O; Andrew R; Olsson T
J Clin Endocrinol Metab; 2002 Jul; 87(7):3330-6. PubMed ID: 12107245
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of 11β-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue and portal hypercortisolism in non-alcoholic fatty liver disease.
Candia R; Riquelme A; Baudrand R; Carvajal CA; Morales M; Solís N; Pizarro M; Escalona A; Carrasco G; Boza C; Pérez G; Padilla O; Cerda J; Fardella CE; Arrese M
Liver Int; 2012 Mar; 32(3):392-9. PubMed ID: 22136330
[TBL] [Abstract][Full Text] [Related]
40. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice.
Hermanowski-Vosatka A; Balkovec JM; Cheng K; Chen HY; Hernandez M; Koo GC; Le Grand CB; Li Z; Metzger JM; Mundt SS; Noonan H; Nunes CN; Olson SH; Pikounis B; Ren N; Robertson N; Schaeffer JM; Shah K; Springer MS; Strack AM; Strowski M; Wu K; Wu T; Xiao J; Zhang BB; Wright SD; Thieringer R
J Exp Med; 2005 Aug; 202(4):517-27. PubMed ID: 16103409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
